Meanwhile, B. Riley FBR downgraded its Galmed Pharmaceuticals Ltd [GLMD] rating to a Neutral from a a Buy in a research note published on May 22, 2020; the price target was decreased to $8 from $11. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who began to cover the stock in early February with a ‘”a Buy”‘ rating. Canaccord Genuity started covering the stock on December 02, 2019. It rated GLMD as “a Buy”.
Price Performance Review of GLMD
On Monday, Galmed Pharmaceuticals Ltd [NASDAQ:GLMD] saw its stock jump 6.37% to $1.67. Over the last five days, the stock has gained 19.29%. Galmed Pharmaceuticals Ltd shares have fallen nearly -47.65% since the year began. Nevertheless, the stocks have fallen -65.21% over the past one year. While a 52-week high of $23.80 was reached on 01/03/25, a 52-week low of $1.21 was recorded on 04/08/25. SMA at 50 days reached $1.8531, while 200 days put it at $3.2300.
Levels Of Support And Resistance For GLMD Stock
The 24-hour chart illustrates a support level at 1.2933, which if violated will result in even more drops to 0.9167. On the upside, there is a resistance level at 2.3633. A further resistance level may holdings at 3.0567. The Relative Strength Index (RSI) on the 14-day chart is 53.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1821, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.71%. Stochastics %K at 66.57% indicates the stock is a holding.
How much short interest is there in Galmed Pharmaceuticals Ltd?
A steep rise in short interest was recorded in Galmed Pharmaceuticals Ltd stocks on 2025-04-15, growing by 47932.0 shares to a total of 96430.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 48498.0 shares. There was a rise of 49.71%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 12, 2018 when B. Riley FBR began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
